REDWOOD CITY, Calif.--(BUSINESS WIRE)--Maxygen, Inc. (Nasdaq:MAXY) today announced that it has submitted a proposal to the Biomedical Advanced Research and Development Authority (BARDA) for a multi-year, multi-million dollar contract for the development of its MAXY-G34 product candidate as a potential medical countermeasure for Acute Radiation Syndrome (ARS). ARS results from exposure to high doses of ionizing radiation, such as from a nuclear explosion, improvised nuclear device detonation or radiation leak from a nuclear power facility. The hematopoietic sub-syndrome of ARS is characterized by the onset of severe neutropenia, which in combination with gastrointestinal and skin damage can lead to opportunistic infections and death.
